Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Venom May Hold Secret to Transplant Rejection

December 2, 2015 By Monash University

The stonefish is one of the world's ugliest and deadliest fish. You'll know if you step on one; the fish protects itself using 13 razor sharp venom filled spines capable of slicing through reef shoes. The stonefish is one of the world’s ugliest and deadliest fish. You’ll know if you step on one; the fish protects itself using 13 razor sharp venom filled spines capable of slicing through reef shoes. The resulting pain is crippling, can last for days and may result in amputation of a limb or death.

Monash University researchers have solved the X-ray crystal structure of the lethal factor present in stonefish venom. The discovery has provided unexpected insight into a crucial human immune response that is responsible for the failure of up to 30 percent of bone marrow transplant therapies for treating leukaemia. The structural insights obtained from stonefish venom are now being used to develop immunosuppressants to improve the success rate of transplant therapies.

The work, published in Proceedings of the National Academy of Sciences of the United States of America (PNAS), reveals that the lethal component of stonefish venom, a protein called Stonustoxin, is an ancient relative of the human immune protein perforin.

In humans, perforin is an essential weapon unleashed to destroy virally infected and cancerous cells. Perforin proteins attach themselves to a diseased cell and assemble to form giant ring shaped holes, or pores, on the cell surface. Each pore contains around 20 perforin proteins that stick together in a symmetrical fashion. The pores are big enough to allow toxins to enter the cell, killing it from within. How these pores form is a mystery but the work on stonustoxin has revealed a key part of the pore assembly mechanism.

To make their discovery, the team used powerful synchrotron radiation to visualise the atomic structure of stonustoxin. Crucially, they found that the toxin contains two perforin-like proteins stuck together. By seeing how two of the proteins first interact, the researchers can build on this to understand how the full assembly of 20 perforin molecules forms a complete pore.

Unravelling the structure of the stonefish’s lethal toxin was carried out at Monash University and the ARC Centre of Excellence in Advanced Molecular Imaging. The leading authors of the study were Dr Andrew Ellisdon, Dr Sheena McGowan and Professor James Whisstock.

“The lethal factor in stonefish venom is like a loaded gun — ready to fire as soon as it is injected into the foot of an unsuspecting victim,” co-lead author Dr Sheena McGowan said.

In humans, unwanted or excessive perforin activity is responsible for a range of medical problems including pancreatic cell destruction in type I diabetes and the rejection of bone marrow transplants in the treatment of leukaemia.

An international group of researchers, led by the Peter MacCallum Cancer Institute and including Monash based Professor Whisstock and his team, are working to develop perforin inhibitors. “Already the structure of stonustoxin is starting to inform our drug development program, and we now understand the very first stages of perforin pore formation. This type of mechanistic information is extremely useful in developing new strategies to inhibit perforin itself,” co-lead author Professor Whisstock said.

“People who step on a stonefish suffer agonising pain because the lethal stonustoxin protein attacks nerves. The treatment for envenomation includes an anti-venom together with soaking the wound in non-scolding hot water — the latter treatment unravels the venom and stops it punching holes,” he said.

Related Articles Read More >

This is a screenshot of the remote robotic surgery technical guidelines appearing in the World Journal of Surgery.
New technical guidelines set to advance remote robotic surgery
An illustration of Embolization Inc.'s Nitinol Enhanced Device (NED).
This nitinol vascular embolization device has another shape memory material up its sleeve
A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
A photo of Johnson & Johnson MedTech's Polyphonic-connected Monarch robotics-assisted bronchoscopy system in the lab.
J&J MedTech’s global head of digital wants to fund your AI project
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe